Development and validation of patient-reported outcomes measures for overactive bladder: A review of concepts

被引:84
作者
Coyne, Karin S.
Tubaro, Andrea
Brubaker, Linda
Bavendam, Tamara
机构
[1] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Univ Roma La Sapienza, Sant Andrea Hosp, Rome, Italy
[3] Loyola Univ, Med Ctr, Dept Obstet, Maywood, IL 60153 USA
[4] Loyola Univ, Med Ctr, Dept Gynecol, Maywood, IL 60153 USA
[5] Loyola Univ, Med Ctr, Dept Urol, Maywood, IL 60153 USA
[6] Pfizer Inc, New York, NY USA
关键词
D O I
10.1016/j.urology.2006.05.042
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patient-reported outcome (PRO) measures are a valuable means for determining how a disease and its treatment affect patients, including effects on health-related quality of life (HROL). To ensure that the results obtained with PROS are clinically useful, data must be gathered using valid and reliable instruments. Developing such instruments requires a multistep, structured process that incorporates cognitive psychology, psychometric theory, and patient and clinician input. The process begins by determining the intent and purpose of the PRO and culminates in studies that demonstrate the measure's validity, reliability, and responsiveness. Several valid and reliable PROS are available for assessing the effects of treatment on symptom severity, symptom bother, and HROL in patients with overactive bladder.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 46 条